Search clinical trials for: Kogenate (BAY14-2222)

Total 250 results

Bayer
Nektar Therapeutics

Completed

Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia

Pneumonia

United States, France
Bayer
Nektar Therapeutics

Completed

Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia (INHALE 1)

Pneumonia, Bacterial

Korea, Republic of, Taiwan, United States, Canada, Philippines, Turkey, Thailand, Australia, Mexico, Colombia, Czechia, Brazil
Bayer

Completed

Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Hemophilia A

Bulgaria
Bayer

Completed

Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment (BONA)

Breast Neoplasms | Prostatic Neoplasms | Multiple Myeloma | Osteolysis

Czech Republic
University Hospital, Caen

Completed

Identification of Anticancer Drugs Associated With Cancer Therapy-related Cardiac Dysfunction: a Pharmacovigilance Study

Heart Failure | Cancer, Therapy-Related

France
Turku University Hospital
University of Turku

Completed

Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging and Biomarkers (IMPROD)

Prostate Cancer

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Influenza Immunization

United States, Poland, Spain, Czechia
Wockhardt
Clinartis

Completed

To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment

Renal Impairment

United States
Radboud University Medical Center
GlaxoSmithKline

Completed

Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

Influenza | Herpes Zoster

Netherlands
Bayer

Completed

Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

Healthy

Germany
Bayer

Completed

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Neoplasms

France, Moldova, Republic of
Botswana Harvard AIDS Institute Partnership
AstraZeneca; Botswana Ministry of Health

Completed

Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2

COVID-19

Botswana
The George Institute

Not yet recruiting

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)

Chronic Kidney Diseases
M.D. Anderson Cancer Center

Active, not recruiting

Glutamine PET Imaging Colorectal Cancer

Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | RAS Wild Type

United States
Organon and Co

Completed

40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)

Bipolar Disorder
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to COVID-19 Vaccination (AICOVI)

SARS-CoV-2 Vaccination

Germany
Bayer
ImmunoGen and MorphoSys

Completed

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Mesothelioma

Belgium, France, United States, Canada, Spain, Turkey, United Kingdom, Australia, Finland, Italy, Poland, Korea, Republic of, Netherlands, Russian Federation
Bayer

Completed

BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease (ARTS)

Heart Failure

Denmark, Germany, Belgium, Austria, Czechia, Israel, Norway, Sweden, Poland, Finland
FHI 360
Bill and Melinda Gates Foundation

Recruiting

Casea S Contraceptive Implants (Casea S) Trial

Contraception

Dominican Republic
Organon and Co

Completed

12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)

Bipolar Disorder
Bayer

Completed

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results (FLAMINGO)

Type 2 Diabetes | Chronic Kidney Disease

United States
Bayer

Completed

Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone (ARTS-HF Japan)

Heart Failure

Japan
Organon and Co

Completed

Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)

Bipolar 1 Disorder
Dantari, Inc.

Completed

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

HER2-negative Metastatic Breast Cancer

United States
Bayer

Completed

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone (ARTS-HF)

Heart Failure

France, Taiwan, United States, Turkey, Spain, Greece, Portugal, Germany, Canada, Austria, Czechia, Denmark, Israel, Korea, Republic of, Poland, South Africa, Sweden, Bulgaria, Italy, Finland, Hungary, Lithuania, Netherlands, Australia, ...
Organon and Co

Completed

Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)

Schizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
Forest Laboratories

Completed

Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)

Bipolar I Disorder

United States
Andrei Iagaru
National Cancer Institute (NCI)

Completed

18F-FSPG PET/CT for Cancer Patients on Therapy

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Metastatic Renal Cell Cancer | Stage III Renal Cell Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Breast Cancer | B-Cell Neoplasm | Stage IIIA Breast Cancer | Stage IV Renal Cell Cancer | Stage IIIC Breast Cancer | Estrogen... and other conditions

United States
University of Aberdeen

Completed

Effect of Fish Oil on Insulin Sensitivity

Type 2 Diabetes Mellitus | Sarcopenia | Metabolic Syndrome X

United Kingdom
Bayer

Recruiting

Prophylaxis Regimen for Hemophilia A Patients (PREDICT)

Hemophilia A | Prophylaxis of Bleeding

United States
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (reSURFACE 1)

Plaque Psoriasis
Forest Laboratories

Completed

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

Bipolar 1 Disorder

United States, Bulgaria, Croatia, India, Philippines, Romania, Russian Federation, Serbia, Turkey, Ukraine
Bayer

Terminated

Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate (ANES)

Prostate Cancer

Czech Republic
Organon and Co

Completed

A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)

Schizophrenia | Schizoaffective Disorder
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
Organon and Co

Active, not recruiting

A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)

Contraception

United States, Puerto Rico
Bayer

Completed

A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe (Safe-CAM)

Prostate Cancer | Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea | Hypersexuality in Men | Sexual Deviations in Men

Spain, Germany, Netherlands, Poland, France
Organon and Co

Completed

Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)

Schizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
Wockhardt

Completed

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

QT/QTc Interval in Healthy Volunteers

United States
Organon and Co

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)

Schizophrenia | Bipolar I Disorder
Organon and Co

Completed

Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898) (ADDRESS-98)

Bipolar Disorder
Vertex Pharmaceuticals Incorporated

Completed

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Chronic Hepatitis C Virus

United States
NeuromaxBionevia

Completed

12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN)

Diabetic Peripheral Neuropathy

Russian Federation
Bayer

Completed

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Ovarian Neoplasms

Belgium, Spain, Moldova, Republic of, United States
University of Utah
Medtronic - MITG

Withdrawn

Efficacy of PENNSAID® for Pain Management in the Emergency Department

Pain | Ankle Sprain

United States
Assaf-Harofeh Medical Center

Completed

Anorectal Application of 5% Lidocaine Cream Reduces Pain Prior to Periprostatic Nerve Block During Transrectal Ultrasound Guided Biopsy

Pain | Prostate Cancer | Rectal/Anal
Blueprint Medicines Corporation

Recruiting

(VELA) Study of BLU-222 in Advanced Solid Tumors

Gastric Cancer | Ovarian Cancer | Carcinosarcoma | Advanced Solid Tumors | Endometrial Cancer | Esophageal Adenocarcinoma | HER2-negative Breast Cancer | CCNE1 Amplification | HR+ Breast Cancer

United States, Italy, United Kingdom
Bayer

Completed

Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.

Energy Expenditure

United States
Bayer
ImmunoGen, Inc.; MorphoSys AG

Completed

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi)

Neoplasms

United States, Spain, United Kingdom, Korea, Republic of, Canada, France, Belgium, Australia, Singapore, Italy, Netherlands, Switzerland

3

Subscribe